Hal E. Broxmeyer, Ph.D. is Distinguished Professor, Mary Margaret Walther Professor Emeritus, and Professor of Microbiology and Immunology, and Co-Leader, Program on Hematopoiesis and Hematologic Malignancies, NCI-Designated Indiana University Simon Cancer Center (since 1990s) at the Indiana University School of Medicine (IUSOM), Indianapolis, IN. He is the former Chairman of Microbiology and Immunology (1997-September 2010), Scientific Director of the Walther Oncology Center (1988-2009), and Professor of Medicine (1986-2009) at the IUSM. He received a BS degree, Brooklyn College, City University of New York (1966), MS degree from Long Island University, Brooklyn Center (1969) and PhD from New York University (1973).  He did post-doctoral training at Kingston General Hospital, Queens University Kingston, Ontario, Canada (1973-1975).  He worked at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City (1975-1983) rising from the rank of Associate Researcher (advanced post-doc) to Associate Member.  He was also Assistant Professor of Biology, Sloan Kettering Division of Cornell University Graduate School of Medical Sciences, New York, before being recruited to the IUSOM in 1983 as an Associate Professor of Medicine and Director of Cancer Research of the Regenstrief Foundation. To date, he has published 789 scientific papers (542 refereed papers and 247 Reviews/Book Chapters). The papers have been cited 64,800 times with an h-factor of 120 and an i10 index of 570 (Google Scholar); with h-factor of 104 (Web of Science) as of Feb. 2019. Dr. Broxmeyer’s Awards include: New York University Founders Day Award (1973); Mellor Award (2^nd prize 1976; 1^st prize 1977) and Boyer Award (1983) from MSKCC; Special Fellow (1976-1978) and Scholar Award (1978-1983) from the Leukemia Lymphoma Society; Merit Award, National Cancer Institute (1987-1995, for his studies on actions of growth factors); Variety Club Award (1992 and 1993), Indiana; Gold Medal of City of Paris (1993); World of Difference Award, Indiana Health Industry Forum (1997); Who’s Who in Health Care, Indianapolis Business Journal (IBJ) (2002); Health Care Heroes Award, IBJ (2002); Karl Landsteiner Award, American Association of Blood Banks (2002); Prestigious External Award Recognition, IUPUI (2003); Distinguished Alumni Award, Long Island University  (2005); Joseph T. Taylor Excellence in Diversity Award, Indiana University (2006); Dirk van Bekkum Award, Autologous Blood and Bone Marrow Society (2006); E. Donnall Thomas Prize and Lecture, American Society of Hematology (2007); Glenn W. Irwin Jr. M.D., Distinguished Faculty Award, Indiana University School of Medicine Alumni Association (2008); State of Indiana General Assembly House Resolution No. 46 (2008); Till and McCulloch Lecture Award from Canadian Blood and Marrow Transplant Group (2010); George Stamatoyannopoulos Lecture Award, American Society of Gene and Cellular Therapy (2010); 2011 International Society of Hematology and Stem Cell Research (ISEH) Donald Metcalf Award; 41^st Annual Schueler Distinguished Lecture in Pharmacology, Tulane Medical School (2013); elected Fellow of the American Association for the Advancement of Science (AAAS), 2012; Honorary Professorship, Peking Union Medical College, Beijing, China, (2014); Thought Leader Award for Cord Blood Transplantation, 15^th Annual International Cord Blood Conference, (2017); NHLBI Outstanding Investigator (R35) Award, (2018).  Dr. Broxmeyer is Chairman Emeritus, Board of Directors, National Disease Research Interchange (NDRI), Philadelphia, PA. He was 1991 President of the International Society for Hematology and Stem Cell Research (ISEH), and was 2010 President, American Society of Hematology (ASH; only non-MD in the history of ASH to become President). His personal research involves mechanisms of regulation of hematopoiesis in context of stem cells/progenitor cells/cytokines.  He uses animal models to evaluate physiological activities of cytokines and cytokine combinations, and the influence of protein truncation by Dipeptidylpeptidase 4 (DPP4/CD26) on cytokine/chemokine activity. His studies on stem/progenitor cell kinetics of patients receiving various cytokines, have suggested means to better utilize these cytokines for efficacious use.  He evaluates alternative sources of transplantable hematopoietic stem and progenitor cells and was a discoverer of the utility of umbilical cord blood for this purpose.  His laboratory studies and first proof of principle cord blood bank in his laboratory set the stage for their clinical use, and he helped design the first clinical transplants that lead to their successful use. The first five of five, and seven of ten transplants of the more than 40,000 now performed were done with cord blood tested and frozen in his laboratory and hand-delivered to the transplant site. His group demonstrated that Extra Physiologic Oxygen Shock/Stress (EPHOSS) when cells are collected/processed in ambient air is detrimental to stem cells, effects mitigated by collecting/processing bone marrow and cord blood in hypoxia (3% O₂) or with cyclosporine A in ambient air, for a more efficacious stem cell collection of potential clinical relevance (Cell, 2015). His laboratory efforts also led to the clinical studies he was involved in that established the hematopoietic stem and progenitor cell mobilizing capability of AMD3100, alone and in synergy with granulocyte colony stimulating factor.  Dr. Broxmeyer served on the Councils of ASH, ISEH, and the Society of Leukocyte Biology.  He served on numerous NIH and ACS study sections including on the NIH Hematology II Study Section twice for 5 years each time (and was Chairman for last 3 years of second term) and was Advisory Member for NHLBI of the NIH.  He has served three 5 year terms as a member of the Scholar, Special Fellow and Fellow grant review committee for the Leukemia Lymphoma Society. He is a long-time member of the advisory cord blood committee of the National Marrow Donor Program (NMDP), and served a two-year term on the HRSA/HHS committee on Blood Stem Cell Transplantation (2008-2010).  He was on the Board of Directors of the first cord blood banking company (Biocyte Corporation). He served as the chairman of the Board of Scientific Councilors, and on the External Advisory Board of the National Space Biomedical Research Institute (NSBRI/NASA). He has been on over 20 scientific Editorial Boards, including Blood, Experimental Hematology, the Journal of Immunology and Blood Cells, Molecules, and Diseases, and is currently on over 10 Editorial Boards,including the Journal of Experimental Medicine, and Stem Cells.  He is Senior Editor, Stem Cells and Development, and Consulting Editor for Journal of Clinical Investigation. His research has been continuously peer-review funded since 1976, and by the NIH since 1978 (usually with multiple NIH grants at the same time).

Recent Key Publications

Broxmeyer, H.E., Hoggatt, J., O’Leary, H.A., Mantel, C., Chitteti, B.R., Cooper, S., Messina-Graham, S., Hangoc, G., Farag, S., Rohrabaugh, S.L., Ou, X., Speth, J., Pelus, L.M., Srour, E.F., Campbell, T.B. 2012. Dipeptidylpeptidase 4 Negatively Regulates Colony Stimulating Factor Activity and Stress Hematopoiesis. Nature Medicine. 18:1786-1796. PMCID:PMC3742313

Mantel, C.R., O’Leary, H.A. Chitteti, B.R., Huang, X., Cooper, S., Hangoc, G., Brustovetsky, N., Srour, E.F., Lee, M.R., Messina-Graham, S., Haas, D.M., Falah, N., Kapur, R., Pelus, L.M., Bardeesy, N., Fitament, J., Ivan, M., Kim, K-S., and Broxmeyer, H.E. 2015. Enhancing hematopoietic stem cell transplantation efficacy by mitigating oxygen shock.  Cell. 161:1553-1565. PMCID:PMC4480616

O’Leary, Capitano, M.L., Cooper, S., Mantel, C., Boswell, S., Kapur, R., Ramdas, B., Chan, R., Deng, L., Skinner, H.D., Qui, C.K., and Broxmeyer, H.E. 2017. DPP4 truncated GM-CSF and IL-3 manifest distinct receptor binding and regulatory functions compared to their full length forms. Leukemia. 31:2468-2478. PMCID:PMC5650952

Guo, B., Huang, X., Lee, M.R., Lee, S.A., and Broxmeyer, H.E. 2018. Antagonism of PPAR-γ signaling expands human hematopoietic stem and progenitor cells by enhancing glycolysis. Nat Med. 24(3):360-367. PMCID:PMC5875416

Huang, XX., Guo, B., and Broxmeyer, H.E. 2018. Neutralizing negative epigenetic regulation by HDAC5 enhances human haematopoietic stem cell homing and engraftment. Nat Commun. 9(1):Article# 2741. PMCID:PMC6048146

Capitano, M., Zhao, L., Cooper, S., Thorsheim, C., Aae, S., Huang, X., Dent, A., Marks, M., Abrams, C.S., and Broxmeyer, H.E. 2018. Phosphatidylinositol Transfer Proteins Regulate Megakaryocyte TGF-b1 Secretion and Hematopoiesis in Mice. Blood. 132:1027-1038.  PMCID:PMC6128088 [Available on 2019-09-06]